Show simple item record

dc.contributor.authorBossa, Matias Nicolas
dc.contributor.authorSahli, Hichem
dc.date.accessioned2024-01-22T15:45:14Z
dc.date.available2024-01-22T15:45:14Z
dc.date.issued2023
dc.identifier.issn2045-2322
dc.identifier.otherWOS:000988352100018
dc.identifier.urihttps://imec-publications.be/handle/20.500.12860/43439
dc.sourceWOS
dc.titleA multidimensional ODE-based model of Alzheimer's disease progression
dc.typeJournal article
dc.contributor.imecauthorSahli, Hichem
dc.contributor.orcidextBossa, Matias Nicolas::0000-0001-5127-2573
dc.contributor.orcidimecSahli, Hichem::0000-0002-1774-2970
dc.date.embargo2023-02-23
dc.identifier.doi10.1038/s41598-023-29383-5
dc.source.numberofpages14
dc.source.peerreviewyes
dc.source.beginpageArt. 3162
dc.source.endpageN/A
dc.source.journalSCIENTIFIC REPORTS
dc.identifier.pmidMEDLINE:36823416
dc.source.issue1
dc.source.volume13
imec.availabilityPublished - open access
dc.description.wosFundingTextThis work was partially funded by INNOVIRIS (Brussels Capital Region, Belgium) under the project: 'DIMENTIA: Data governance in the development of machine learning algorithms to predict neurodegenerative disease evolution' (BHG/2020-RDIR-2b). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organisation is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record